The microtubule-associated protein Tau is strongly implicated in Alzheimer's disease (AD) and aggregates into neurofibrillary tangles in AD. Genetic reduction of Tau is protective in several animal models of AD and cell culture models of amyloid-β (Aβ) toxicity, making it an exciting therapeutic target for treating AD. A variety of evidence indicates that Tau's interactions with Fyn kinase and other SH3 domain-containing proteins, which bind to PxxP motifs in Tau's proline-rich domain, may contribute to AD deficits and Aβ toxicity. Thus, we sought to determine if inhibiting Tau-SH3 interactions ameliorates Aβ toxicity. We developed a peptide inhibitor of Tau-SH3 interactions and a proximity ligation assay (PLA)-based target engagement assay.
(1:250, Santa Cruz SC-434) primary antibodies were used, and Goat anti-rabbit conjugated with Alexa-594, (ThermoFisher, A-11037, 1:1000) secondary antibody was used to view Tau.
Imaging and quantification was completed using the same methods described for the HEK-293
PLA.
Statistics. Sample sizes were determined based on power calculations to provide 80% power to detect a difference of 20% with 30% standard deviation at an alpha of 0.05 using the effect size from preliminary studies or from literature. All statistical tests were performed using Graphpad Prism 7, and appropriate statistical tests were used based on the number and types of groups for each experiment. Amelioration of Aβo toxicity was defined as a significant Results:
Tau reduction ameliorates Aβo toxicity
We first replicated the beneficial effects of Tau reduction in a primary hippocampal neuron model of Aβo toxicity. We applied a previously published Tau antisense oligonucleotide (ASO) (18) , which after 1 week of exposure reduced Tau levels to about half of normal levels ( Figure 1A,B ). Six days after treatment with either the Tau ASO or a nontargeting control (NTC)
ASO (18), we applied 2.5 μM synthetic Aβo (characterized in Supplementary Figure 1 
Tau-PxxP 5/6 inhibits Tau-SH3 interactions
To determine whether the beneficial effects of Tau reduction would be replicated by demonstrates that Tau-PxxP 5/6 did not change Tau, Fyn, or GAPDH levels (Student's t-test, t(10)=1.86, p = 0.092; t(9)=0.28, p = 0.79; t(10) =1.78, p = 0.10, respectively, n=5-6 wells per group). on tau phosphorylation measured by Western blot ( Figure 3A ). As expected, Tau-PxxP 5/6 reduced Y18 phosphorylation of Tau by Fyn ( Figure 3B ).
J o u r n a l P r e -p r o o f
This effect likely results from reduced Tau-Fyn interaction but could be due to direct Fyn inhibition by Tau-PxxP 5/6 . To distinguish between these possibilities, we examined Fyn's regulatory phosphorylation status. Fyn autophosphorylation at Y420 is associated with active Fyn kinase and assessing phosphorylation at this site is a commonly used measure of Fyn kinase activity (33) . Importantly, we found that Tau-PxxP 5/6 did not change phosphorylation status of Fyn at Y420, providing no evidence for a change in Fyn activity ( Figure 3C ). As positive controls, the Fyn kinase inhibitor PP2 decreased pY420 ( Supplementary Figure 4) , and ethanol, which activates Fyn kinase activity (34) , increased pY420 (Supplementary Figure 5 ).
Together, these results support the hypothesis that Tau 
Tau-PxxP 5/6 inhibits endogenous Tau-Fyn interaction in neurons.
Since Tau-PxxP 5/6 inhibits the Tau-Fyn interaction when the proteins are overexpressed in HEK-293 cells, we next used PLA to determine if Tau-PxxP 5/6 inhibits endogenous Tau-Fyn interaction in neurons, achieving the intended pharmacodynamic effect and allowing us to infer target engagement. This also provided the opportunity to visualize the amount and localization of endogenous Tau-Fyn interaction in neurons ( Figure 4A ). Interestingly, the interaction predominantly occurred throughout the neurites rather than in the soma and appeared adjacent to, but not directly within, Tau 
Inhibiting Tau-SH3 interactions ameliorates Aβo toxicity
With validated tools in hand for inhibiting Tau-SH3 interactions in neurons, we next asked if inhibiting Tau-SH3 interactions ameliorated Aβo toxicity in primary neurons, mimicking the beneficial effects of Tau reduction. We assessed Aβo toxicity using two orthogonal measures: membrane trafficking abnormalities and neurite degeneration.
First, we tested whether inhibiting Tau-SH3 interactions prevented Aβo-induced membrane trafficking abnormalities. We pretreated DIV20 neurons with Tau-PxxP 5/6 or its vehicle control for 90 minutes before applying 2.5 μM Aβo or their vehicle control for 24 hours and utilizing the same modified MTT assay described earlier ( Figure 5A ). Tau-PxxP 5/6 ameliorated Aβo-induced membrane trafficking abnormalities in a dose-dependent manner, while the negative control peptide, Tau-CTD, did not ( Figure 5B ).
J o u r n a l P r e -p r o o f Second, we tested another Aβo-induced abnormality that is ameliorated by Tau reduction (25) , Aβo-induced neurite degeneration. Aβo causes neurite degeneration and blebbing, which can be quantified using immunofluorescent labeling of MAP2 followed by imaging in an unbiased manner using a high-content, automated approach (see Supplementary   Figure 9 ). As before, we pretreated DIV20 neurons with Tau-PxxP 5/6 or its vehicle control for 90 minutes before applying 2.5 μM Aβo or their vehicle control ( Figure 6A ). Forty-eight hours after
Aβo application, we fixed the neurons, labeled MAP2, then quantified intact neurite length. Tau-PxxP 5/6 ameliorated neurite blebbing and degeneration while Tau-CTD did not ( Figure 6B ,C).
J o u r n a l P r e -p r o o f
Together, these findings provide evidence that Tau-SH3 interactions contribute to Aβo toxicity in neurons. This study demonstrates that an inhibitor of Tau-SH3 interactions ameliorates Aβo toxicity in primary rat neurons, supporting the idea that inhibiting Tau-SH3 interactions is a potential mechanism by which Tau reduction is protective. We developed several novel tools for studying Tau-SH3 interactions. One is a proximity ligation assay for the most well studied Tau- One question that will need to be addressed in ongoing studies is which particular Tau-SH3 interactions are most critical. The field has focused on Fyn as a prototypical SH3containing binding partner for Tau (35) and considerable evidence suggests a role for Tau-Fyn interactions in AD. First, Tau directly binds Fyn's SH3 domain (23, 24, 36, 37) and both Tau phosphorylation and Tau mutations increase Tau-Fyn interaction (23, 38) . Second, Tau and Fyn have converging phenotypes both in vitro and in vivo. In primary neurons, genetic knockout of either Tau (25) or Fyn (26) ameliorates Aβo toxicity. In vivo, reduction of either Tau (8, (10) (11) (12) (13) (14) 39) or Fyn (40) prevents Aβo-induced dysfunction, and Tau reduction decreases susceptibility to network hyperexcitability (11, 18) . Third, Fyn overexpression exacerbates Aβo-induced neuronal J o u r n a l P r e -p r o o f dysfunction (41) and Tau reduction prevents these Fyn-dependent effects (11 (48) and found that phosphorylation of BIN1 modulates the interaction and that there is altered BIN1 phosphorylation in AD brain. Of note from the in silico study of SH3-Tau-PxxP interactions (42) was that the strongest binding for BIN1's SH3 domain in Tau's proline-rich domain was the 5 th J o u r n a l P r e -p r o o f PxxP motif. Additionally, PSD95 interacts via its SH3 domain with Tau at the synapse, forming a complex with Fyn and NMDARs (44) , and manipulations that disrupt this Tau/Fyn/PSD95 complex prevent network hyperexcitability and and Aβ toxicity in vivo (49) . This complex allows Fyn to phosphorylate NMDARs which could lead to increased Ca 2+ influx and excitotoxicity (50) .
Thus, multiple different Tau-SH3 interactions could contribute to Aβo-induced neuronal dysfunction.
Another remaining question is whether Aβo promotes increased Tau-SH3 interactions as a mechanism leading to neuronal deficits, or whether Tau On the other hand, and perhaps more likely, Tau-SH3 interactions could be permissive of Aβo toxicity, even if Aβo does not lead directly to more or stronger Tau-SH3 interactions.
Considering the prototypical SH3-containing protein Fyn, extracellular Aβo activates Fyn when it is anchored to the post-synaptic density so that Fyn phosphorylates its targets. One study suggested that Tau traffics Fyn to dendrites and anchors it to the post-synaptic density (12) . (53) that is implicated in Aβ-induced dysfunction in vivo (54) .
Our results support the idea of targeting Tau-SH3 interactions as a novel Tau-directed therapeutic strategy for AD. These data provide preclinical evidence supporting the potential efficacy of inhibiting Tau-SH3 interactions; however, considering the potential of a novel strategy also requires evaluating safety and tractability. While further studies are clearly needed, there is evidence to suggest that inhibiting Tau-SH3 interactions would be safe. Even complete removal of Tau, which de facto would prevent all Tau-SH3 interactions, does not cause dramatic abnormalities in animals (55) (56) (57) (58) (59) , and even the rather subtle changes in Tau knockout mice are not seen in Tau heterozygous mice with partial Tau reduction (19, 60-62), which better represent the incomplete block that would be provided by Tau-SH3 interaction inhibitors. In fact, Tau reduction with antisense oligonucleotides did not have apparent adverse effects in mouse models (18, 63) and human clinical trials using this approach have been underway since 2017, as yet without reported adverse effects. In terms of tractability, inhibiting protein-protein interactions was once thought to be an unrealistic strategy for small molecule therapies, but advances in drug discovery and design have mitigated these concerns (64) . We have already conducted high-throughput screening for Tau-SH3 interaction inhibitors, using a Tau-Fyn interaction assay, and identified multiple series of chemically tractable hits (23) . Much is left to learn, but the data presented here provide initial preclinical support for the concept of targeting Tau-SH3 interactions as a therapeutic strategy for AD.
